Contributing to Cancer Patients and the Healthcare Sector
First written in FY2016. 3 of 4 entries say "Restated". Latest entry: FY2025.
4 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「The Group’s basic management policy is to contribute to healthcare in Japan and other Asian countries by licensing promising new drug candidates from pharmaceutical companies and biotech ventures in Japan and overseas, conducting development activities centered on clinical development in Japan and other Asian countries, and supplying products to the pharmaceutical market.」
The Group continues to pursue its basic policy of contributing to healthcare in Japan and other Asian countries through the licensing of candidate products, clinical development and product supply. - FY2022RestatedAnnual report
「The Group’s basic management policy is to contribute to healthcare in Japan and other Asian countries by licensing promising new drug candidates from pharmaceutical companies and biotech ventures in Japan and overseas, conducting development activities centered on clinical development in Japan and other Asian countries, and supplying products to the pharmaceutical market.」
The Group continues to pursue its basic policy of contributing to healthcare in Japan and Asia through licensing candidate products, clinical development and market supply. - FY2017RestatedAnnual report
「The Group’s basic management policy is to contribute to healthcare in Japan and other Asian countries by licensing promising new drug candidates from pharmaceutical companies and biotech ventures in Japan and overseas, conducting development activities centered on clinical development in Japan and other Asian countries, and supplying products to the pharmaceutical market.」
The Group continues to position its contribution to healthcare as a basic business policy. - FY2016First statedAnnual report
「The Company was established in 2006 with the aim of contributing to healthcare in Japan and other Asian countries by licensing promising drug candidates from pharmaceutical companies and biotechnology ventures in Japan and overseas, conducting development activities centered on clinical trials in Japan and other Asian countries, and supplying products to pharmaceutical markets.」
The Company identifies contributing to healthcare as its founding purpose and explains that its business serves to improve patients’ quality of life through cancer treatments and products that alleviate adverse events associated with treatment.